Fisher & Paykel Healthcare launches new Evora™ compact nasal mask for sleep apnea


Fisher & Paykel Healthcare Corporation Limited announced today the launch of F&P Evora, a new nasal mask for the treatment of obstructive sleep apnea (OSA).
 
F&P Evora is a compact nasal mask that sits comfortably under the nose. The mask features CapFit™ headgear, which is designed to be put on like a baseball cap in one simple and intuitive movement. In a clinical trial*, 98 per cent of participants described Evora as “simple to take off and put on in the dark,” and 95 per cent of respiratory therapists found the mask “simple to fit.”
 
Evora also features a ‘floating’ seal, which sits inside stability wings. These technologies work together to allow for freedom of movement during sleep while keeping the mask comfortably in place. 
 
“Evora offers OSA patients the performance benefits of a nasal mask, with the streamlined design and minimalism of a nasal pillow mask,” said Lewis Gradon, Managing Director and CEO of Fisher & Paykel Healthcare. “Its unique and innovative features make fitting the mask much easier for the patient and the respiratory therapist. We’re excited to bring it to market.”




F&P Evora will initially be available in Australia and New Zealand from February, followed by Canada and Europe. It will be launched in other countries upon receiving clearances.
 
Evora has one-sized headgear and four seal sizes – small, medium, large and wide. For more information, visit www.fphcare.com/evoranasal.

*20 out of 21 respiratory therapists rated the simplicity of the Evora nasal mask as very simple or simple to fit. Internal validation study conducted with 21 respiratory therapists in United States of America 2019. 2. 43 out of 44 participants were able to put on and take off the Evora nasal mask, once fitted, in the dark. Internal validation study conducted with 44 participants in United States of America 2019.

 

About Fisher & Paykel Healthcare

Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in respiratory care, acute care, surgery and the treatment of obstructive sleep apnea.  The company’s products are sold in over 120 countries worldwide. For more information about the company, visit our website www.fphcare.com.

 

Ends

 

Contact

Investors:

Hayden Brown
Investor Relations Manager
hayden.brown@fphcare.co.nz
+64 (0) 27 807 8073

 

Media:

Karen Knott
Senior Communications Manager
karen.knott@fphcare.co.nz
+64 (0) 21 713 911